The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P
Originalsprog | Engelsk |
---|---|
Tidsskrift | Journal of Headache and Pain |
Vol/bind | 13 |
Udgave nummer | 4 |
Sider (fra-til) | 271-5 |
Antal sider | 5 |
ISSN | 1129-2369 |
DOI | |
Status | Udgivet - 2012 |
ID: 40186358